Key Points
- Insider Manuela Valente sold 2,376 shares on April 7 at an average price of $4.87 for $11,571, executing the trade under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding and reducing her stake to 219,275 shares (a ~1.07% decrease).
- Several other senior executives (CEO, CFO, CTO, president and others) also made modest, planned sales under 10b5‑1 plans to cover taxes; these transactions are small relative to insider holdings but could produce short‑term selling pressure.
- SOPH trades around $4.86 with a 52‑week range of $2.58–$5.70 and a market cap of about $333M, while analyst coverage is mixed (two Buys, one Sell) with an average price target of $7.00.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $4.87, for a total value of $11,571.12. Following the completion of the sale, the insider directly owned 219,275 shares in the company, valued at $1,067,869.25. This represents a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Manuela Valente also recently made the following trade(s):
- On Monday, April 6th, Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $12,595.45.
- On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $1,820.20.
SOPHiA GENETICS Price Performance
NASDAQ:SOPH opened at $4.86 on Thursday. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The company has a market cap of $332.86 million, a P/E ratio of -9.53 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The stock's 50-day simple moving average is $4.77 and its 200 day simple moving average is $4.68.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. As a group, sell-side analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently issued reports on SOPH shares. Guggenheim upped their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 26th. BTIG Research reiterated a "buy" rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $7.00.
Check Out Our Latest Stock Report on SOPHiA GENETICS
Trending Headlines about SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Neutral Sentiment: CEO Jurgi Camblong executed two Rule 10b5‑1 sales (2,600 and 2,500 shares at ~$4.85–4.86). CEO still holds ~3.7M shares. SEC filing
- Neutral Sentiment: CFO George Cardoza reported multiple small sales (~2,520; 2,413 shares) under a 10b5‑1 plan to cover taxes; remaining holdings stay large (~292–295k shares). SEC filing
- Neutral Sentiment: CTO Abhimanyu Verma sold several tranches (2,519; 1,030 shares) under a 10b5‑1 plan; still owns ~204–205k shares. SEC filing
- Neutral Sentiment: President Ross Muken and other senior managers (Philippe Menu, Zhenyu Xu, Manuela Valente, Well Daan Van, Kevin Puylaert) reported multiple planned sales of ~600–2,700 shares each to cover tax obligations; each filing cites Rule 10b5‑1 plans. Representative filings: Menu, Xu, Valente. Menu SEC filing
- Neutral Sentiment: Collectively the insider sales are modest relative to total insider holdings and were executed under pre‑arranged plans (tax withholding stated as purpose), which reduces negative informational signal but can still create short-term selling pressure.
Hedge Funds Weigh In On SOPHiA GENETICS
A number of institutional investors have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after buying an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC increased its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC acquired a new position in SOPHiA GENETICS during the third quarter worth approximately $6,708,000. Archon Capital Management LLC increased its position in SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock worth $2,061,000 after buying an additional 14,342 shares during the last quarter. Finally, Royce & Associates LP acquired a new position in SOPHiA GENETICS during the fourth quarter worth approximately $2,009,000. Institutional investors and hedge funds own 31.59% of the company's stock.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
